Evidence map›Paper›PMID 37671310›Full record

ReviewCancer diagnosis & prognosis

Impact of Amplified Oncogenes on Salivary Gland Carcinomas.

Vasileios Papanikolaou, Aristeidis Chrysovergis, Asimakis D Asimakopoulos, Despoina Spyropoulou, Vasileios Ragos, George Papanastasiou, Sotirios Papouliakos, Sofianiki Mastronikoli, Dimitrios Roukas, Evangelos Tsiambas and 7 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 4 countries.

Vasileios PapanikolaouFirst Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
Aristeidis ChrysovergisFirst Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
Asimakis D Asimakopoulos *Department of Otorhinolaryngology, Centre Hospital, Sion, Switzerland.
Despoina Spyropoulou *Department of Radiation Oncology, Medical School, University of Patras, Patras, Greece.
Vasileios Ragos *Department of Maxillofacial, Medical School, University of Ioannina, Ioannina, Greece.
George Papanastasiou *Department of Maxillofacial, Medical School, University of Ioannina, Ioannina, Greece.
Sotirios PapouliakosDepartment of Otolaryngology, Gennimatas GNA Hospital, Athens, Greece.
Sofianiki MastronikoliBrighton and Sussex Medical School, Brighton, U.K.
Dimitrios RoukasDepartment of Psychiatry, 417 Veterans Army Hospital (NIMTS), Athens, Greece.
Evangelos TsiambasDepartment of Cytology, 417 Veterans Army Hospital (NIMTS), Athens, Greece.
Pavlos PantosFirst Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
Dimitrios PeschosDepartment of Physiology, Medical School, University of Ioannina, Ioannina, Greece.
Nicholas MastronikolisDepartment of Otolaryngology, Medical School, University of Patras, Patras, Greece.
Loukas ManaiosDepartment of Surgery, BIOCLINIC, Thessaloniki, Greece.
Panagiotis FotiadesDepartment of Surgery, 424 Army Hospital, Thessaloniki, Greece.
Antonis VylliotisDiagnostic and Research Lab BIOCLAB, Athens, Greece.
Efthymios KyrodimosFirst Department of Otolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
University of Ioannina · GRHippocration General Hospital · GRNational and Kapodistrian University of Athens · GRUniversity of Patras · GR424 General Military Hospital · GRBrighton and Sussex Medical School · GBGeneral Hospital of Athens G. Genimatas · GRHôpital de Sion · CHInstitute of Cytology · RUNIMTS Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In normal epithelia, proto-oncogenes regulate critical intra- or intercellular functions, including cell growth and proliferation, apoptosis, and signaling transduction from the cell periphery (extracellular space) to the nucleus mediated by different pathways. Oncogenes are the mutated or amplified forms of the corresponding proto-oncogenes that are crucially involved in cell neoplastic and malignant transformation during carcinogenesis. Salivary gland carcinomas (SGCs) demonstrate a variety of histogenetic types. They are characterized by a broad spectrum of chromosomal and gene alterations. In particular, amplifications in specific genes [human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 4 (HER4), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), Mouse double minute 2 homolog (MDM2), androgen receptor (AR), programmed death (ligand 1 (PD-L1), neurogenic differentiation factor 2 (NEUROD2), phosphatidylinositol 3,4,5-trisphosphate-dependent RAC exchanger 1 protein (PREX1), cyclin-dependent kinase4/6 (CDK4/6), proline-rich acidic protein 1 (PRAP1), kell antigen system (KEL), glutamate receptor subunit epsilon 2 (GRIN2D), Ewing sarcoma RNA-binding protein 1 (EWSR1), MYC proto-oncogene (MYC)] combined or not with chromosomal numerical imbalances (aneuploidy/ polysomy/monosomy) form different genetic signatures affecting the response to monoclonal antibody-based, oncologicaly targeted regimens. Different SGC histotypes demonstrate specific combinations of mutated/amplified genes that modify their clinicohistological features. In the current molecular review, we present the most important amplified oncogenes and their impact on the biological behavior of SGCS.

Indexed as

amplificationcarcinomaglandoncogenereviewSalivary

Identifiers

PMID37671310
PMCPMC10475925
OpenAlexW4386371637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.